Information memorandum regarding Photocure's divestment of Metvix®
(Thomson Reuters ONE) - Reference is made to the stock exchange notice dated 1 October 2009in relation to Photocures divestment of Metvix® to Galderma for EUR51 million. Please find attached the information memorandum inconnection with the divestment of Metvix®, in compliance with section3.5 of the Oslo Stock Exchange's continuing obligations of stockexchange listed companies.For further information, please contact:President and CEO Kjetil HestdalE-mail: kh(at)photocure.noMobile: +47 913 19 535Office: +47 22 06 22 10CFO Christian FeketeE-mail: cf(at)photocure.noMobile: +47 916 42 938Office: +47 22 06 22 10www.photocure.comAbout PhotocurePhotocure is a Norwegian pharmaceutical company listed on the OsloStock Exchange (OSE: PHO). The company develops and sellspharmaceuticals and medical devices for the photodynamic treatmentand diagnosis of cancer and selected dermatology indications.Photocure's commercial activities includes own marketing and sales inselected markets as well as out-licensing to leading pharmaceuticalcompanies on a regional or global basis prior to phase III.Photocure has one proprietary pharmaceutical product on the market:Hexvix®, for the diagnosis of bladder cancer. Hexvix is approved inEU and under priority review by FDA in the US. In addition, thecompany has developed a proprietary light source, which is used incombination with the Visonac(TM) cream. Through worldwide studies,Photocure is continuously testing its products for new indications,and the aim is to develop a pipeline of follow-on products based onthe Photocure Technology(TM) platform.For more information about Photocure, visit our website atwww.photocure.com.http://hugin.info/131151/R/1350411/325824.pdfhttp://hugin.info/131151/R/1350411/325825.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 27.10.2009 - 14:05 Uhr
Sprache: Deutsch
News-ID 7460
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Information memorandum regarding Photocure's divestment of Metvix®"
steht unter der journalistisch-redaktionellen Verantwortung von
Photocure ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
